Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic Ulcers
NCT ID: NCT02742233
Last Updated: 2017-08-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
60 participants
INTERVENTIONAL
2015-11-30
2017-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes
NCT01472432
Accelerated Wound Healing in Diabetic Ulcers by Sitagliptin
NCT02675335
Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers
NCT00796744
Treatment of PRP on Diabetes Wound
NCT02088268
Evaluation of the Safety Follow-up of Becaplermin or Placebo Gel Following Treatment of Chronic, Full Thickness Diabetic Ulcers
NCT00740922
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Diabetic ulcers, saxagliptin + Regular treatment.
Diabetic ulcers, placebo + Regular treatment.
Time Point:
Initial treatment;
Post-treatment ( 1w );
Post-treatment ( 2w );
Post-treatment ( 4w );
Completely healed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
saxagliptin
saxagliptin \& Regular treatment:
saxagliptin, brand name，Bristol-Myers, Squibb, dose: 5mg, po, qd
saxagliptin
Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.
Treatment Period: Participants will receive saxagliptin with regular treatment
placebo
placebo \& Regular treatment:
placebo, dose: 5mg, po, qd
placebo
Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.
Treatment Period: Participants will receive placebo with regular treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
saxagliptin
Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.
Treatment Period: Participants will receive saxagliptin with regular treatment
placebo
Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.
Treatment Period: Participants will receive placebo with regular treatment
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ulcer located on the legs or feet, stage III or IV (Wagner Classification System)
* The subject agrees to comply with study protocol requirements and all follow up visit requirements.
Exclusion Criteria
* Ulcer infection
* Non-diabetic ulcers Orthopedic or neuromuscular pathologic conditions
50 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Long Min,MD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Long Min,MD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hongting Zheng, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Department of Endocrinology,The Second Affiliated Hospital, Third Military Medical University, Chongqing, People's Republic of China.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Second Affiliated Hospital, Third Military Medical University
Chongqing, Chongqing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XinqiaoH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.